Catalent Appoints First President of Asia Pacific
New President Named for Softgel Technologies Business Unit
Somerset, NJ – September 9, 2013 — Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, has named David Heyens in the new role of President of Catalent Asia Pacific. Reporting directly to Catalent’s President and CEO, John Chiminski, Mr. Heyens will drive Catalent’s growth in the region following the company’s recent expansion into China, and will build on Catalent’s well-established regional operations in Japan, Australia and Singapore.
“This appointment comes at an important moment in our business, as we launch our two new joint ventures in China, for softgel technologies and clinical supplies, and focus more growth resources in Asia Pacific,” said Mr. Chiminski. “Bringing Dave’s proven leadership to this region is hugely beneficial for both our customers and our business.”
Replacing Mr. Heyens as the President of Catalent Softgel Technologies will be Aris Gennadios, Ph.D. Also reporting to Mr. Chiminski, Dr. Gennadios will have full strategic responsibility for the market-leading global softgel development, delivery and supply business with 10 global manufacturing facilities that deliver the leading share of global pharmaceutical, generic and consumer health softgel products to markets worldwide.
“Aris is an outstanding leader and a widely respected industry veteran, known for his expertise and passion for delivering better treatments for patients across an ever expanding set of challenging molecules in softgel drug delivery technology” said Mr. Chiminski. “We are very excited to have him join our executive team and extend the momentum and growth that we are driving in our flagship business.”
David Heyens was named President of Catalent’s Softgel Technologies business in June 2007. Since joining Catalent in 1995, he has served in a variety of capacities, including as President of packaging services, Senior Vice President of Global Sales and Marketing, President of North America Softgel Technologies, and as General Manager for the Canadian softgel business. Prior to joining Catalent, Heyens held leadership roles in sales and marketing at Baxter and Procter & Gamble. He has a bachelor’s degree in business administration and marketing from St. Clair College of Applied Arts and Technologies in Canada.
Dr. Gennadios began his pharmaceutical industry career in 1996 as an R&D scientist in softgel technology. In 2002, he joined Catalent in business development for both advanced technologies and development solutions. After holding several business development roles of increasing responsibility, he assumed an operational leadership position as General Manager of the company’s Somerset, N.J site. In 2010, Dr. Gennadios became Vice President and General Manager of Catalent’s Rx Softgel Technologies business, and became Vice President and General Manager of the overall global Softgel Technologies business in 2012. Gennadios earned his bachelor’s degree in chemical engineering from the National Technical University of Athens, Greece, and his master’s degree in biological engineering from Clemson University. He holds a doctorate in engineering from the University of Nebraska as well as an MBA from Wake Forest University.
To arrange for an interview with Mr. Chiminski, Mr. Heyens or Dr. Gennadios please contact Chris Halling at Catalent, +44 (0) 7580 041073 or email@example.com.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com .